Peripheral vascular bypass (PVB) refers to the surgical revision of blood flow to restore perfusion distal to an occluded or otherwise disrupted arterial segment. PVB procedures can involve any of the arteries excluding those in the heart or the brain. These open surgical procedures are typically done by vascular surgeons, cardiologists, or interventional radiologists.[1][2][3]
PVB procedures can be accomplished via anastomosis with any of the main arteries except those located in the head.[4][5][6]
Arteries within the upper extremity and chest that may require bypass include:
Arteries often bypassed within the lower extremity include:
Arteries often bypassed with the abdomen include:
PVB is applied in the management of certain traumatic arterial injuries, or aneurysms, and most commonly for peripheral arterial disease (PAD). PAD is the result of atherosclerotic plaque causing stenosis of the arteries supplying the lower extremities. Symptoms of PAD range from asymptomatic, to demand ischemia or claudication, to Critical Limb Ischemia (CLI), characterized by severe disability and tissue loss. For these patients, PVB is considered if they have severe disease burden that is not amenable to endovascular therapy, or they have failed therapy previously. Lesions that are not responsive include severe stenosis and hostile vascular anatomy which would make endovascular treatment technically challenging. [7][8]
The contraindications for PVB are similar to those for other surgeries. Many patients with the peripheral vascular disease have other comorbidities, including cardiac and respiratory dysfunction. Patients with a history of previous cardiac intervention (stenting, angioplasty or coronary artery bypass) or low ejection fraction have a high perioperative mortality. The same holds true for patients with respiratory illness, such as chronic obstructive pulmonary disease. Thus, any patient undergoing PVB should have and thorough cardiac and respiratory work-up prior to surgery. [9][10][11]
The equipment used in PVB surgery involves many of the same surgical tools as other procedures. However, there are some unique instruments worth mentioning.
Tunneler: Used to tunnel bypass conduits through deep tissue
DeBakey Clamps: Used to clamp large vessels temporarily
Bulldog Clamps: Used to clamp medium-sized vessels temporarily
Vessel loops: Rubber loops used to easily identify vessels and to temporarily occlude them if needed
Doppler: Ultrasound probe that identifies audio waveforms of blood flow
Castro-Viejo: Precision needle driver for passing suture
Prolene Suture: This is the favored suture material for vascular anastomoses. It is a permanent monofilament suture.
Heparin: Anticoagulation. Given systemically or locally to prevent clotting during vascular clamping
Vascular surgery is considered a high-risk procedure and most procedures carry a >5% risk of an acute cardiac event. Direct reconstruction of aorta iliofemoral disease is associated with a 2.8% perioperative mortality while extra-anatomic bypass confers an 8.8% mortality. Mortality increases in patients with a chronic obstructive pulmonary disease, advanced age, pre-existing cardiac disease, diabetes, renal failure and need dialysis, and tobacco use. Under this pretense, accurate risk stratification is warranted in patients undergoing PVB.
Methods
PVB procedures can vary depending on patient anatomy and location of the arterial obstruction. However, for most cases, there are common configurations to redirect the flow. The key to a functional bypass is to establish the proximal and distal anastomoses in disease-free regions.
Conduits for bypass include artificial grafts (polyteraflouroethylene and Dacron) and autologous saphenous vein (reversed, non-reversed, and in situ). For most infra-inguinal bypasses, an autologous vein graft is preferred. Aortoiliac bypasses require conduits with a larger lumen. Thus synthetic grafts are commonly used.
Patients undergoing PVB are at risk for wound infection, bleeding, pneumonia, conduit occlusion, and peripheral nerve damage. These patients often have also a higher prevalence of cerebrovascular and coronary artery disease which significantly increases their risk for stroke and myocardial infarction surgery. Indicators for potential adverse outcomes include smoking, pulmonary disease, female sex, diabetes mellitus, previous bypass history, and advanced age. Conduit related complications can be divided into immediate and long-term. Immediate including acute thrombosis and bleeding. Long-term including infection and occlusion secondary to intimal hyperplasia.
Postoperatively, the patient's distal flow to posterior tibial and dorsalis pedis should be assessed. If the pulses are not palpable, a doppler should to used for identification. Patients should be discharged on a statin, along with aspirin and/or clopidogrel. If they have a synthetic conduit, dual therapy should be considered. Follow-up should include periodic evaluations of symptoms, pedal pulses, and Ankle-Brachial Index. Duplex ultrasound is the best non-invasive technique to assess graft patency.
PVB can help perfuse obstructed limbs. However, peripheral vascular disease is a progressive disorder with no cure. Clinicians including pharmacists and nurses should instead educate patients on prevention of PVD. This means discontinuing smoking, maintaining a healthy body weight, controlling diabetes, lowering cholesterol and remaining physically active. These lifestyle changes have more durable benefits than most bypass procedures.
PVB is not a benign procedure and is associated with serious complications that also include death.
[1] | Siah MC,Abramowitz S, Perfusion Assessment and Treatment in the Diabetic Patient. Clinics in podiatric medicine and surgery. 2019 Jul; [PubMed PMID: 31079603] |
[2] | Shukla M,Callas PW,Lahiri JA,Alef MJ,Keating FK,Stanley AC,Steinthorsson G,Schneider DJ,Bertges DJ, Surveillance and Management of Troponin Elevation after Vascular Surgery. Annals of vascular surgery. 2019 May 7; [PubMed PMID: 31075460] |
[3] | Yanagisawa W,Gomes ML,Menting TP,Deloose KR,Varcoe RL, The current state of surgical bypass versus drug eluting stents for long femoropopliteal occlusive lesions. The Journal of cardiovascular surgery. 2019 May 2; [PubMed PMID: 31062570] |
[4] | Powell R,Menard M,Farber A,Rosenfield K,Goodney P,Gray B,Lookstein R,Pena C,Schermerhorn M, Comparison of specialties participating in the BEST-CLI trial to specialists treating peripheral arterial disease nationally. Journal of vascular surgery. 2019 May; [PubMed PMID: 31010516] |
[5] | Levin SR,Arinze N,Siracuse JJ, Lower extremity critical limb ischemia: A review of clinical features and management. Trends in cardiovascular medicine. 2019 Apr 15; [PubMed PMID: 31005554] |
[6] | Markovic MD,Cvetkovic SD,Koncar IB,Dragas MV,Markovic DM,Kukic BP,Kuzmanovic IB,Dimic AD,Sladojevic MM,Davidovic LB, Treatment of pediatric vascular injuries: a single referral non-pediatric centre experience. International angiology : a journal of the International Union of Angiology. 2019 Apr 15; [PubMed PMID: 30994319] |
[7] | Wang C,Chen J,Gu C,Qiao R,Li J, Impact of risk factors and surgical techniques in coronary endarterectomy: a network meta-analysis. Interactive cardiovascular and thoracic surgery. 2019 Apr 14; [PubMed PMID: 30982903] |
[8] | Phair J,Carnevale ML,Teveris VG,Koleilat I,Indes JE, Peripheral arterial occlusive disease operative case volume in the final years of 5 2 and 0 5 vascular training paradigms. Surgery. 2019 Apr 6; [PubMed PMID: 30967238] |
[9] | Singh N,Zeng C,Lewinger JP,Wolfson AM,Shavelle D,Weaver F,Garg PK, Preoperative hemoglobin A1c levels and increased risk of adverse limb events in diabetic patients undergoing infrainguinal lower extremity bypass surgery in the Vascular Quality Initiative. Journal of vascular surgery. 2019 Mar 6; [PubMed PMID: 30852042] |
[10] | Khan A,Brienesse S,Boyle A,Collins N, Percutaneous treatment of saphenous vein graft aneurysm: Contemporary procedural considerations. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography [PubMed PMID: 30737966] |
[11] | Forster R,Liew A,Bhattacharya V,Shaw J,Stansby G, Gene therapy for peripheral arterial disease. The Cochrane database of systematic reviews. 2018 Oct 31; [PubMed PMID: 30380135] |